Abbvie Inc (NYSE:ABBV) And Alpine Immune Sciences Inc. (NASDAQ:ALPN) Enter Partnership To Develop ALPN-101

Abbvie Inc (NYSE:ABBV) and Alpine Immune Sciences Inc. (NASDAQ:ALPN) have announced an exclusive global license and option agreement for Alpine’s best in class dual ICOS/CD28 costimulation antagonist, ALPN-101. AbbVie to co-develop ALPN-101 with Alpine ICOS and CD28 are important costimulatory molecules playing critical roles in inflammatory autoimmune diseases. Alpine’s ALPN-101 is a potent ICOS and […]

AbbVie Inc (NYSE:ABBV) Expresses Confidence In Humira’s Defense Strategy On The International Scale

AbbVie Inc (NYSE:ABBV) AbbVie understands that its business performance is closely linked and even dependent on what happens as Humira. There are reports that Humira is experiencing some existential threats and that is considering the different moves by a large number of US copycats. AbbVie says that there is still hope left as it cites […]

AbbVie Inc (NYSE:ABBV)’s HUMIRA® Approved As First Self-Administering Treatment For Crohn’s Disease In Children

Boston, MA 09/26/2014 (wallstreetpr) – AbbVie Inc (NYSE:ABBV)’s drug HUMIRA® (adalimumab) has gained authorization from the U.S. Food and Drug Administration to treat children suffering from Crohn’s disease if they fail to show significant improvements from currently available treatment means. Alternative Treatment According to PR Newswire news, the company announced its latest achievement with HUMIRA […]

AbbVie Inc (NYSE:ABBV) To Make Several Presentations Proposing New Drugs For Cancer And Tumor Therapies

Boston, MA 09/23/2014 (wallstreetpr) – AbbVie Inc (NYSE:ABBV) announced that will be presenting findings from new researches at the annual meeting of the European Society of Medical Oncology. As mentioned in the PR Newswire article, the conference will be held from Sept 26 through Sept 30, 2014 in Madrid, Spain. AbbVie Inc (NYSE:ABBV) has been […]

Biogen Idec Inc (NASDAQ:BIIB) And AbbVie Inc (NYSE:ABBV) Reveal Data Confirming Zinbryta Superiority to Avonex in Reducing Annualized Relapse Pace

Boston, MA 09/15/2014 (wallstreetpr) – Global biotech company, Biogen Idec Inc (NASDAQ:BIIB) and research-based pharmaceutical company AbbVie Inc (NYSE:ABBV) disclosed that their Phase three DECIDE clinical study has exhibited a vast improvement in reducing disease activity in people affected by relapsing-remitting multiple sclerosis or RRMS. Phase III Results The companies revealed that the drug candidate, […]

Medtronic, Inc. (NYSE:MDT) To Reimburse Top Executives, Directors For Inversion Taxes Bills

Boston, MA 09/02/2014 (wallstreetpr) – Medtronic, Inc. (NYSE:MDT) will compensate its top executives and directors for the tax imposed on their stock and option awards in relation to the inversion efforts that the company is undertaking, Wall Street Journal stated in an article. The company seeks to shift its corporate office from the U.S. through […]

Abbvie Inc (NYSE:ABBV), Pfizer Inc. (NYSE:PFE) Struck In Tax Inversions Amid Political Pressure; Walgreen Company (NYSE:WAG) To Remain Headquartered In Illinois Despite Boots’ Acquisition

Boston, MA 08/07/2014 (wallstreetpr) – Walgreen Company (NYSE:WAG) on August 6, 2014 announced about its plan for shelling out approximately $15.3 billion for acquisition of Alliance Boots’ portion that it does not own yet. However, Walgreen said that it will not be using this deal for corporate inversion. The shares of company sunk to the […]

AbbVie Inc (NYSE:ABBV) And Abbott Laboratories (NYSE:ABT) To Face Consolidated Lawsuits In Chicago

Boston, MA 06/09/2014 (wallstreetpr) – AbbVie Inc (NYSE:ABBV) and Abbott Laboratories (NYSE:ABT) are alleged to hide risks associated with the testosterone substitute AndroGel. Both the Chicago based drug makers are to face lawsuits in a court in Chicago now while several cases over the same issue are already pending in the U.S. District Court. Judge […]

Abbott Laboratories (NYSE:ABT) May Face Legal Action – ABBV

Boston, MA 10/24/2013 (wallstreetpr) – An investigation has been launched by a law firm into potential violations of securities laws concerning the demerger of Abbott Laboratories (NYSE:ABT) and AbbVie Inc (NYSE:ABBV). Abbott had announced the demerger in October 2011 as the businesses had evolved in two separate entities. Abbott would continue to focus on drug manufacturing and […]